Edgewise Therapeutics announced positive results from its Phase 2 CANYON trial of sevasemten for Becker muscular dystrophy, showing a 28% average decrease in creatine kinase levels compared to placebo and a 77% decrease in troponin I levels; the trial included 40 adults and 29 adolescents.